Chronic Lymphocytic Leukemia

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in December 2025 spanning tumor types.

Experts reflect on pivotal data, emerging agents, and highly-anticipated trends spanning CML, CLL, B-cell lymphomas, and other hematologic malignancies.

Pitrobrutinib monotherapy showed significant efficacy improvements in first-line CLL/SLL compared with BR treatments.

Zanubrutinib plus venetoclax maintained a 36-month PFS rate of 87% (95% CI, 78.6%–92.4%) in treatment-naive CLL/SLL.

Zanubrutinib shows sustained 6-year efficacy and safety in treatment-naive CLL/SLL, outperforming BR with durable PFS and high response rates.

Final data from the BRUIN trial show pirtobrutinib achieved an 81.6% ORR and durable outcomes with a favorable safety profile in previously treated CLL/SLL.

Zanubrutinib displayed long-term PFS and responses in patients with relapsed/refractory CLL/SLL.

Pirtobrutinib yields superior overall response rates and promising progression-free survival compared with ibrutinib in chronic lymphocytic leukemia.

Lisaftoclax demonstrated efficacy and safety for the treatment of patients with relapsed/refractory CLL/SLL.

In the CaDAnCe-101 study, BGB-16673 was tolerable, effective, and showed sustained disease control in high-risk, heavily pretreated, relapsed/refractory CLL/SLL.

Fixed-duration venetoclax combinations delivered PFS comparable with continuous ibrutinib in the phase 3 CLL17 trial.

Ahead of the 2025 ASH Annual Meeting, OncLive spoke with experts in CLL care to preview the most anticipated meeting abstracts.

The FDA has granted traditional approval to pirtobrutinib for covalent BTK inhibitor–exposed, relapsed/refractory CLL or SLL.

Read the most notable updates to the latest versions of the NCCN Clinical Practice Guidelines in Oncology across tumor types ahead of 2026.

Aaron Gerds, MD, MS, discusses the role of BTK inhibitors in CLL, real-world data with CAR T-cell therapies in LBCL, and JAK inhibitors for myelofibrosis.

A meta analysis found BTK inhibitors carry risks of hypertension, atrial fibrillation, and hemorrhage, underscoring the need for cardiovascular monitoring.

The removal of REMS programs for approved CAR T-cell therapies could enable improved access and streamlined management of hematologic malignancies.

BTK inhibitor therapy improved PFS vs chemoimmunotherapy in NOTCH1-mutated CLL, highlighting the value of NOTCH1 screening to guide treatment selection.

The in vivo CAR T-cell therapy UB-VV111 has received fast track designation from the FDA for the management of relapsed/refractory LBCL and CLL.

Workshop faculty shared insights on first-line, R/R, and post-BTKi CLL care, plus sequencing, shared decision-making, and emerging therapies.

An indirect comparison of SEQUOIA and CLL14 shows zanubrutinib improved PFS over venetoclax/obinutuzumab in treatment-naive CLL after baseline adjustment.

Paolo Ghia, MD, PhD, details the final analysis of the phase 2 CAPTIVATE study evaluating frontline ibrutinib/venetoclax in patients with CLL.

The FDA has approved TAR-200 in urothelial cancer and selumetinib in pediatric NF-1–associated inoperable plexiform neurofibromas, and more.

The novel BTK degrader led to fast-onset responses that were maintained over time in patients with CLL/SLL.

Topline results from the BRUIN CLL-313 study show a significant improvement in PFS with pirtobrutinib vs chemoimmunotherapy in treatment-naive CLL/SLL.